ABCG2 and cancer: In summary, this study showed that afatinib could reverse the drug resistance and enhance the cytotoxicity of conventional anticancer drugs in ABCG2-overexpressing cancer cells by a dual inhibition of ABCG2: inhibiting the drug transport function and downregulating the expression of ABCG2.